Dublin, Dec. 09, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/hj5xvg/antibodydrug) has announced the addition of the "Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis" report to their offering.
This report describes and analyzes the situation of antibody-drug conjugates as of November 2015 regarding
- ADC pipeline
- ADC technologies
- ADC stakeholders
- ADC business opportunities and commercial perspectives.
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis is based on the analysis of more than 90 companies, more than 100 ADC drug profiles and more than 26 ADC technologies and components.
Although the initial enthusiasm about antibody-drug conjugates has made room for a more realistic understanding, the prospects for success of ADC drug candidates remain good and are based on a well-filled pipeline, increasing adoption of next generation ADC technologies, lessons learned from failures, a balanced mixture of stakeholders and a variety of options for funding of ADC developments. About 70 ADCs are in clinical and pre-IND stages of development and at least the same number of ADC programs are in preclinical R&D.
For the first time in 2015, combined sales of the approved and marketed ADC products Adcetris and Kadcyla will surpass the sales limit of US$ 1 billion. The pipeline of ADCs and immunoconjugates in advanced clinical development gives the chance of approval of further ADCs in the near- and mid-term future. The clinical attrition rate of ADCs is lower, i.e. better, than that of conventional, naked antibodies in oncology. The availability of next generation ADC technologies allows to select case by case the appropriate linker and payload. Site-specific conjugation technologies with and without engineering of the antibody generate homogenous products. Novel payloads provide the basis for enhanced antitumor activity.
Nearly all major pharma and biotech companies have ADC programs, although with different strategies of how to gain access to ADC technologies. Few have established proprietary in-house capabilities, most still rely on outside technology providers. However, the duopoly of conventional ADC technology providers is converting into a more differentiated, heterogenous field of ADC technologies and technology providers.
Key Topics Covered:
1 Executive Summary
2 ADC Pipeline Analysis
2.1 Overview
2.2 Next-to-market ADCs
2.3 Next-to-market Immunoconjugates
2.4 ADCs in Early Clinical Development
2.5 ADCs in IND-Enabling Studies
2.6 ADCs in Preclinical R&D
2.7 Competition among ADCs for the Same Target
2.8 Discontinued ADCs and Clinical Attrition Rate
3 ADC Technology Analysis
3.1 Overview
3.2 Conventional and Emerging ADC Technologies
3.3 Probodies and Novel Preclinical Stage Carriers
3.4 Carrier Systems
3.5 Site-Specific Conjugation Technologies with Antibody Engineering
3.6 Site-Specific Conjugation Technologies without Antibody Engineering
4 ADC Stakeholder Analysis
4.1 Major Pharma and Biotech Companies
4.2 Small and Medium Biopharmaceutical Companies
4.3 ADC Technology and Pipeline Companies
4.4 Companies with Novel Payload Technologies
4.5 Companies with Linker, Conjugation & Carrier Technologies
4.6 Companies with Alternative Targeting Moieties
5 ADC Business Analysis
5.1 Overview of Commercial Opportunities and Perspectives with ADCs
5.2 Commercialization of Approved ADCs
5.3 Fund-Raising
5.4 Mergers and Acquisitions
5.5 Pharma - Biotech Collaboration & Licensing Deals
5.6 Biotech - Biotech Collaboration & Licensing Deals
6 ADC Drug Profiles
6.1 Clinical Stage ADC Drug Profiles
6.2 Pre-IND and Preclinical Stage ADC Drug Profiles
6.3 Immunoconjugate Drug Profiles
6.4 Discontinued ADC Drug Profiles
7 ADC Company Profiles
7.1 Major Pharma and Biotech Companies
7.2 Small and Medium Biopharmaceutical Companies
7.3 ADC Technology & Pipeline Companies
7.4 ADC Payload Companies
7.5 ADC Linker, Carrier & Conjugation Technology Companies
7.6 Companies with Alternative Targeting Moieties
8 References
9 ADDENDUM
Companies Mentioned
- 3SBio
- ACES Pharma
- ADC Therapeutics
- APO-T
- AbbVie
- Ablynx
- Affilogic
- Affitech
- Alethia Biotherapeutics
- Alteogen
- Ambrx
- Amgen
- Angiochem
- Antikor Biopharma
- Asana Biosciences
- Astellas Pharma
- AstraZeneca
- BIND Therapeutics
- Bayer HealthCare Pharmaceuticals
- Bicycle Therapeutics
- Biotest
- Blend Therapeutics
- Bristol-Myers Sqibb
- Catalent Pharma Solutions (Redwood Bioscience)
- Celgene
- Celldex Pharmaceuticals
- Centrose
- CureMeta
- CytRx
- CytomX Therapeutics
- Daiichi Sankyo
- Delenex Therapeutics
- Dophen Biomed
- Eisai
- Eli Lilly
- Endocyte
- Formation Biologics
- Fosun Pharma
- Genmab
- GlaxoSmithKline
- Glycotope
- Hanwha Chemical
- Heidelberg Pharma
- Helix BioPharma
- Igenica Biotherapeutics
- Immune Pharmaceuticals
- ImmunoGen
- Immunomedics
- Innate Pharma
- Janssen (Johnson & Johnson)
- Kairos Therapeutics
- LegoChem Biosciences
- LinXis
- Meditope Biosciences
- Menarini
- Merck Serono
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Mistubishi Tanabe Pharma
- MultiCell Immunotherapeutics
- NBE Therapeutics
- NanoCarrier
- Nerviano Medical Sciences
- Novartis
- OntoChem
- Oxford BioTherapeutics
- Oxis Biotech
- Pfizer
- Pharmamar
- Philogen
- Polytherics (Abzena)
- Progenics Pharmaceuticals
- Quanta Biodesign
- Regeneron Pharmaceuticals
- Roche
- Sanofi
- Scil Proteins
- Seattle Genetics
- Serina Therapeutics
- Sorrento Therapeutics (Concortis Biosystems)
- Stemcentrx
- Sutro Biopharma
- SynAffix
- Synta Pharmaceuticals
- Synthon Biopharmaceuticals
- Takeda Pharmaceutical Co
- WuXi PharmaTech
- Zhejiang Medicine Co.
- Zova Biotherapeutics
- Zymeworks
For more information visit http://www.researchandmarkets.com/research/hj5xvg/antibodydrug